Analyses of human CML samples revealed that expression of FAM167A in CD34+ cells from ABL mutation-independent imatinib-resistant patients is significantly higher than that in CD34+ cells from imatinib responders and ABL mutation-dependent imatinib-resistant patients. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.